Clinical Trials · NCT02113657
T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
- Phase
- EARLY_Phase 1
- Recruitment status
- Completed
- Sponsor
- M.D. Anderson Cancer Center
- Enrollment
- 30
- Start date
- Aug 2014
- Locations
- 1 site, United States
- Primary endpoint
- Impact of Ipilimumab on T Cell Responses to prostate cancer neoantigens in both primary tumor and metastatic sites in men with metastatic CRPC